For depression and/or anxiety. ANDA 213063, held by Taro. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 213063 (Doxepin Hydrochloride), held by Taro, was first approved by FDA on Jul 1, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Doxepin Hydrochloride Capsules, USP are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2020 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 10MG BASE · capsule;oral | Doxepin Hydrochloride | Discontinued |
| Doxepin HydrochlorideEQ 25MG BASE · capsule;oral | Doxepin Hydrochloride | Discontinued |
| Doxepin HydrochlorideEQ 50MG BASE · capsule;oral | Doxepin Hydrochloride | Discontinued |
| Doxepin HydrochlorideEQ 75MG BASE · capsule;oral | Doxepin Hydrochloride | Discontinued |
| Doxepin HydrochlorideEQ 100MG BASE · capsule;oral | Doxepin Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters